Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on February 21, 2024. The report addresses a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a regulatory milestone and does not contain financial statements.
Material Changes
On February 21, 2024, the United States Patent and Trademark Office (USPTO) granted the Company's U.S. Patent Application No. 18/113,458. This patent covers the proprietary formulation of oral liquid hydrocortisone for the Company's ET-400 product candidate.
- Patent Expiration: 2043
- Regulatory Status: Expected to be listed in the FDA's Orange Book upon product approval.
- Pipeline Status: Additional patent applications related to the product are currently under review with the USPTO.
Outlook, Risks, and Management Commentary
Management highlighted the successful patent grant as a significant milestone for the ET-400 product candidate. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard regulatory process for Orange Book listing pending product approval.
Investor Verification Checklist
- Verify the listing of the granted patent in the FDA's Orange Book once ET-400 receives approval.
- Monitor the status of additional patent applications currently under review with the USPTO.
- Review the attached press release (Exhibit 99.1) for further details on the proprietary formulation.
- Confirm the 2043 expiration date for the granted patent in official USPTO records.